Order Article Reprints

Le Goubey J-B, Lasnon C, Nakouri I, Césaire L, de Pontville M, Nganoa C, Kottler D, Aide N. ¹⁸F-FDG PET/CT versus Diagnostic Contrast-Enhanced CT for Follow-Up of Stage IV Melanoma Patients Treated by Immune Checkpoint Inhibitors: Frequency and Management of Discordances over a 3-Year Period in a University Hospital. Diagnostics. 2021; 11(7):1198. https://doi.org/10.3390/diagnostics11071198

Le Goubey, Jean-Baptiste, Charline Lasnon, Ines Nakouri, Laure Césaire, Michel de Pontville, Catherine Nganoa, Diane Kottler, and Nicolas Aide. 2021. "¹⁸F-FDG PET/CT versus Diagnostic Contrast-Enhanced CT for Follow-Up of Stage IV Melanoma Patients Treated by Immune Checkpoint Inhibitors: Frequency and Management of Discordances over a 3-Year Period in a University Hospital" Diagnostics 11, no. 7: 1198. https://doi.org/10.3390/diagnostics11071198

Le Goubey, J.-B., Lasnon, C., Nakouri, I., Césaire, L., de Pontville, M., Nganoa, C., Kottler, D., & Aide, N. (2021). ¹⁸F-FDG PET/CT versus Diagnostic Contrast-Enhanced CT for Follow-Up of Stage IV Melanoma Patients Treated by Immune Checkpoint Inhibitors: Frequency and Management of Discordances over a 3-Year Period in a University Hospital. Diagnostics, 11(7), 1198. https://doi.org/10.3390/diagnostics11071198